Jonathan Rubin - 19 Feb 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: SVP, Chief Medical Officer
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 19 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 21 Feb 2025, 16:44:36 UTC
Previous filing: 29 Jan 2025
Next filing: 24 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SUPN	Common Stock						6,905	19 Feb 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Employee Stock Option (Right to Buy)	Award	$0	+20,000		$0.000000	20,000	19 Feb 2025	Common Stock	20,000	$33.52	Direct	F2
transaction	SUPN	Restricted Stock Unit	Award	$0	+4,500		$0.000000	4,500	19 Feb 2025	Common Stock	4,500		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an aggregate of 310 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2	The option vests in four equal annual installments beginning on February 19, 2026.
F3	Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F4	These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.